Palisade Bio Doses First Patient in Phase 2b Trial of PALI-2108 for Ulcerative Colitis

• Palisade Bio dosed the first patient in its global Phase 2b ASCENTRA-UC trial of PALI-2108 for moderately to severely active ulcerative colitis.
• The placebo-controlled study targets approximately 204 patients, testing two once-daily oral doses with clinical remission at Week 12 as the primary endpoint.
• Topline results from the 12-week induction period are expected in the fourth quarter of 2027.
• A seven-day, uncontrolled Phase 1b cohort showed clinical response in all five patients; two achieved clinical remission.
• PALI-2108, an investigational oral PDE4 inhibitor prodrug, was generally well tolerated in Phase 1, with no serious adverse events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280832PRIMZONEFULLFEED9854724) on October 28, 2026, and is solely responsible for the information contained therein.